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Background: The ﬁrst choice for treatment of neonatal convulsions is intravenous phenobarbital, which contains propylene
glycol (PG) as a solvent. Although PG is generally considered safe, the dosage can exceed safety thresholds in neonates.
High PG levels can cause lactic acidosis.
Purpose/Hypothesis: To investigate a relationship between brain PG concentration and medication administered to neo-
nates, and to study if a correlation between spectroscopically detected PG and lactate was present.
Study Type: Retrospective.
Population: Forty-one neonates who underwent MRI/MRS.
Field Strength/Sequence: Short echo time single voxel MRS at 1.5T.
Assessment: Spectra were quantiﬁed. Concentrations of PG were correlated with medication administered, because intra-
venously administered phenobarbital solutions contained 10, 25, or 50 mg phenobarbital per ml, all containing 350 mg
PG per ml. The interval between medication and MRI/MRS was determined.
Statistical Tests: Chi-square test, Student’s t-test, Mann–Whitney U-test and Spearman correlation.
Results: Eighteen neonates had brain PG >1 mM (median 3.4 mM, maximum 9.5 mM). All 18 neonates with high brain PG
and 14 neonates with low brain PG (<1 mM) received phenobarbital as the only source of PG. Nine neonates did not receive
any phenobarbital/PG-containing medication. Neonates with high brain PG more often received 10 mg/ml phenobarbital,
resulting in higher PG dose (high vs. low brain PG (median [interquartile range]: 1400 [595] vs. 350 [595] mg/kg, respectively,
P < 0.01). In addition, the interval between the last phenobarbital dose and MRI was shorter in the high brain PG group (high
vs. low brain PG: 16 [21] vs. 95 [83] hours, respectively, P < 0.001). Within neonates that received phenobarbital, there was
no conclusive correlation between spectroscopically detected PG and lactate (Spearman’s rho = 0.23, P = 0.10).
Data Conclusion: These MRS ﬁndings may increase awareness of potentially toxic PG concentrations in the neonatal brain
due to intravenous phenobarbital administration and its dependence on the phenobarbital formulation used.
Level of Evidence: 4
Technical Efﬁcacy: Stage 5
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PROPYLENE GLYCOL (PG), or propane-1,2-diol, is asolvent that improves solubility and stability of various
intravenous drugs, including phenobarbital, which is the
treatment of ﬁrst choice for neonatal convulsions. PG is "gen-
erally regarded as safe" by the US Food and Drug Adminis-
tration (FDA).1 The World Health Organization (WHO)
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recommends a dose limit of PG of 25 mg per kg body weight
per day as a food additive,2 but this limit does not address its
use as a drug solvent. The European Medicines Agency
(EMA) guidelines adhere to a safety threshold of 50 mg per
kg body weight per day in children below 5 years of age and
a safety threshold of 1 mg per kg body weight per day in
term and preterm neonates.3 The latter is based on the low
clearance of PG in this particular age group.4–6 Indeed, when
intravenous drugs containing PG as a solvent are used, daily
doses of PG exceeding these upper limits are regularly admin-
istered to hospitalized neonates.5–7
The pharmacokinetics of PG in children, and even
more in neonates, are largely unknown. PG is eliminated
through the kidneys or metabolized in the liver through alco-
hol dehydrogenase to lactate and pyruvate8,9; both elimina-
tion routes are dose- and concentration-dependent.8 As a
result of a lower metabolic hepatic capacity and immature
renal function, clearance of PG is lower in children and neo-
nates compared with adults.4 In more detail, PG clearance is
low in neonates, especially in those born preterm and with
lower birth weight, with a half-life varying between 10.8 and
30.5 hours (mean 19.3 hours).8,10 Therefore, neonates are at
risk for PG accumulation and even adverse effects due to
toxicity.
Short-term adverse events of PG (with doses of up to
3 g per day in preterm neonates with body weight below
1500 g) have been reported and include lactic acidosis, renal
failure, hepatic dysfunction, intravascular hemolysis, and sei-
zures, as well as cardiac and respiratory problems.1,3,10–12 On
the other hand, no short-term biochemical impact was
observed when preterm infants received 34 mg per kg body
weight per day of PG for a maximum of 48 hours,7 even
though this dose is above the recommended upper limits.2,3
Nevertheless, long-term effects due to apoptosis have been
described in animal studies,13 although they are unknown in
infants.
Several studies have reported high plasma concentra-
tions after repeated doses of drugs containing PG as a
solvent,4,14,15 and its presence in cerebrospinal ﬂuid has been
shown using in vitro high-resolution magnetic resonance
spectroscopy (MRS).16 In the early years of clinical in vivo
MRS, detection of PG in brain of newborns who received
phenobarbital has been reported17 and has been conﬁrmed by
others.18 In our hospital, neonates are referred to a clinical
MRI examination for various reasons including asphyxia,
infection, or stroke. This examination also includes a single-
voxel 1H MRS covering the basal ganglia and the thalamus,
since this is an area vulnerable to hypoxic damage. In several
neonatal spectra, we detected extremely high signals of a dou-
blet at 1.13 ppm, suggestive of PG. Therefore, we investi-
gated if there was a relationship between the observed
concentration of PG and the type of medication that the
newborns received. There had been a change in phenobarbital
formulation from 50 mg/ml to 10 mg/ml due to market
withdrawal by the manufacturer. All phenobarbital formula-
tions contained 350 mg/ml PG, resulting in a 5-fold increase
in PG dose. We hypothesized that this may be an explanation
for the extremely high brain PG concentrations. In addition,
since high PG levels can lead to lactic acidosis,3,19,20 we stud-
ied if a correlation between concentrations of PG and lactate
measured in neonatal MR spectra was present.
Materials and Methods
Subjects
This study was a retrospective cohort study in neonates (born at ges-
tational age 24–42 weeks) admitted to our Neonatal Intensive Care
Unit between January 2016 and January 2018. As evaluated by our
Medical Ethics Review Committee, the Medical Research Involving
Human Subjects Act did not apply to this study, and therefore there
was a waiver of informed consent.
Neonates were only included if they received a cerebral MRI
at 1.5T, including MRS, as part of standard neonatal care between
birth and 4 weeks after expected date of birth. If medical records
were unavailable for review, neonates were excluded. Forty-seven
neonates were eligible for inclusion; ﬁve infants were excluded
because cerebral MRI was performed at 3T; one infant was excluded
because of insufﬁcient quality of the MRS due to motion. Reasons
for clinical MRI/MRS examination of these 41 included neonates
were perinatal asphyxia (n = 22), perinatal infection (n = 5), perina-
tal stroke (n = 8), metabolic disease with hyperammonemia (n = 1),
and miscellaneous diagnoses (n = 5), including Prader–Willi syn-
drome (n = 2), neuromuscular disease (n = 1), ﬁfth day ﬁts (n = 1),
and epilepsy due to SCN2A mutation (n = 1).
We retrospectively collected birth data (ie, gestational age
[weeks], birth weight [g], mode of delivery) as well as data on medi-
cation containing PG as a solvent. In our study, the only adminis-
tered medication containing PG was intravenous phenobarbital,
either with a concentration of 50 mg/ml, 25 mg/ml, or
10 mg/ml. All phenobarbital formulations used contained 350 mg
PG per ml. The concentration, dosage, and timing of phenobarbital
were collected from medical records. Up until January 2017, a phe-
nobarbital formulation containing 50 mg/ml phenobarbital was
used. From February 2017 onwards, the supply of phenobarbital
50 mg/ml to our Neonatal Intensive Care Unit was not possible due
to market withdrawal by the manufacturer and, therefore, a formula-
tion containing 10 mg/ml phenobarbital was used. Neonates referred
from other hospitals were locally treated with either 10, 25, or
50 mg/ml phenobarbital formulations. The cumulative dose of PG
per kg body weight was calculated. Furthermore, the interval in
hours between MRS and last dose of phenobarbital was determined
and the chronological age (days) at the moment of MRI/MRS was
recorded.
MRS Acquisition and Analysis
During MRI, all neonates were placed in a special cushion to main-
tain adequate positioning and prevent movement artifacts. Most
infants were ventilated during the procedures, whereas some were
spontaneously breathing. A large part of the ventilated infants
received some sedation with intravenous morphine and midazolam;
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in some infants intravenous midazolam was also part of the treat-
ment of neonatal convulsions. Infants who were breathing spontane-
ously were fed half an hour prior to MRI and did not receive
additional sedation.
Clinical MRI/MRS was performed at 1.5T (Avanto, Siemens,
Erlangen, Germany) using an 8-channel head coil. MRI included
T1- and T2-weighted sequences as well as diffusion-weighted imag-
ing. 1H MRS was performed with point-resolved spectroscopy locali-
zation, positioned at the level of the right basal ganglia and
thalamus, volume-of-interest (VOI) 14 ml (20 mm RL, 35 mm AP,
20 mm SI). VOI localization is shown in Fig. 1. In four subjects,
the VOI was slightly smaller (8–12 ml). In another four subjects, a
VOI of 8 ml was selected in the parietal cortex. Repetition time
(TR) 3000 msec, echo time (TE) 30 msec, 32 averages. For ﬁve
spectra (three in basal ganglia/thalamus and two in the cortex),
64 averages were acquired. Single-acquisition reference measure-
ments without water suppression (TR 10,000 msec) using both head
and body coil as receiving coils were obtained for quantiﬁcation,
using the transmitter reference amplitude of the body coil.21 Total
spectroscopic acquisition time was 2 minutes (or 4 min in the case
of 64 averages). Metabolite concentrations were calculated with
LCModel,22 using a basis set including a model spectrum of PG18
and simulating macromolecular and lipid signals.
Concentrations were determined in mM (ie, mmol/l VOI).
Quality parameters estimated by LCModel included the Cramer–
Rao lower bounds for each metabolite, estimated spectral linewidth
(full-width at half-maximum [FWHM], expressed in Hz) and signal-
to-noise-ratio (SNR). Because of variability in size and number of
averages, we reported a normalized SNR corresponding to the stan-
dard protocol of 14 ml and 32 averages. In addition, we checked the
correlation coefﬁcients between metabolite concentrations of PG,
lactate, and lipid signals around 1.3 ppm. We also estimated the
contribution of cerebrospinal ﬂuid (CSF) within the VOI on the T2-
weighted images.
Statistical Analysis
Categorical variables were reported as frequencies (%). Normally dis-
tributed continuous variables were reported as mean with standard
deviation (mean ± SD). Skewed continuous variables were reported
as median with interquartile range (median, IQR). Neonates were
classiﬁed in two groups: brain PG >1 mM (high brain PG) and
brain PG <1 mM (low brain PG). Above the threshold of 1 mM,
the doublet of PG was clearly visible in the qualitative spectra that
were processed on the scanner and could also be quantiﬁed with
Cramer–Rao lower bounds below 20% (see Results section). Cate-
gorical variables were compared using chi-square tests. Normally dis-
tributed data were compared with Student’s t-test, and skewed data
with Mann-Whitney U-tests (for comparison of two groups). Non-
parametric correlations were evaluated with Spearman’s rho, two-
tailed. All analyses were performed using IBM SPSS Statistics
v. 22.0 (Armonk, NY). P < 0.05 was considered signiﬁcant.
Results
In the group of 41 included neonates, the median gestational
age was 40.0 weeks (range 29.4–41.9 weeks), median birth
weight was 3190 g (range 1120–4400 g). Median chronolog-
ical age at MRI/MRS was 4.5 days (range 0.8–20.4 days).
VOIs had a mean CSF partial volume contribution of
4.2 ± 2.0%. The doublet at 1.13 ppm that was visually
detectable in many spectra was ﬁtted reliably by PG. In 18 of
the 41 neonates, concentrations of PG were above 1 mM
(high brain PG), varying between 1.3–9.5 mM, with a
median of 3.4 mM. Spectra and corresponding ﬁts of PG
and lactate for a few infants are shown in Fig. 2. Whereas PG
is easiest recognized by the doublet at 1.13 ppm correspond-
ing to the methyl group, the PG spectrum also contains high
signals of the methylene protons around 3.5 ppm, which
partly overlap with the resonance of myo-inositol. The spec-
trum of the infant with hyperammonemia showed not only
high PG, but also extremely elevated glutamine (Fig. 2D). As
a side note, we remark that in these neonatal spectra gluta-
mine was determined with a median Cramer–Rao lower
bound of 15%, while concentrations of glutamine and gluta-
mate were not correlated with each other (median correlation
coefﬁcient of −0.08).
As expected, Cramer–Rao lower bounds for PG
decreased with increased PG concentrations, with a median
value of 8.5% in the high PG spectra, and at least 26% for
the low PG spectra. In individual spectra, lactate and PG
FIGURE 1: Visualization of VOI. VOI with size of 14 ml (20 mm RL, 35 mm AP, 20 mm SI) is shown in A: sagittal T1-weighted slice at
the center position; B: transverse T2-weighted slice at most inferior position; C: transverse IR-weighted slice at the most superior
position. In this infant the contribution of CSF to the VOI was 4.9%.
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were neither correlated with each other (median correlation
coefﬁcient 0.08), nor with lipid signals around 1.3 ppm
(median correlation coefﬁcients were −0.22 and 0.15
between lactate and Lip13a and Lip13b, respectively; 0.0 and
0.09 between PG and Lip13a and Lip13b, respectively).
Estimates of spectral quality did not differ between the
high and low brain PG groups. Median linewidth was
1.46 Hz (1.02) and 1.97 Hz (1.46), respectively (P = 0.058)
and mean normalized SNR was 16.8 ± 5.4 and 16.3 ± 3.2,
respectively (P = 0.71).
There were no differences in birth data between infants
with high brain PG compared with those with low brain PG,
except for a higher mortality in the high brain PG group
(Table 1). In the latter group, causes of death were perinatal
asphyxia (n = 4), perinatal infection (n = 1), perinatal stroke
(n = 2), and metabolic disease (n = 1). Within the high brain
PG group, there was no difference in diagnosis between those
deceased and those alive (chi-square test χ2 = 4.5, P = 0.34).
In all cases, the cause of death was not directly related to PG.
A total of 32 neonates received at least one dose of pheno-
barbital before the MRS examination. There was no signiﬁcant
difference regarding total dose of phenobarbital administered
between the high and low brain PG groups (40 [10] mg per kg
vs. 30 [20] mg per kg, respectively, P = 0.065). The more fre-
quent administration of 10 mg/ml phenobarbital to neonates
with high brain PG resulted in a higher median dose of
1400 mg PG per kg body weight compared with 350 mg per
kg body weight in the low brain PG group (Table 1).
The observed brain PG concentration as a function of
the cumulative dose of PG administered is shown in Fig. 3.
In neonates with a high cumulative dose, both high and low
brain PG concentrations were observed. To evaluate the effect
of the interval between the last dose of phenobarbital and the
MRS examination, we distinguished short and long intervals
based on the median interval of 30 hours in the total group
(Fig. 3). The median interval in neonates with high PG was
16 hours and was shorter than the median interval of 95 hours
in the low PG group (Table 1).
FIGURE 2: LCModel output with residuals and ﬁts of propylene glycol (PG, red) and lactate (Lac, blue). A: Gestational age
(GA) 37 weeks, birth weight (BW) 2975 g; subependymal hemorrhage; PG = 9.5 mM with Cramer–Rao lower bound (CRLB) 3%,
Lac = 1.1 mM with CRLB 16%. B: GA 41 weeks, BW 4035 g; perinatal asphyxia and 72-hour therapeutic hypothermia; PG = 3.3 mM
with CRLB 8%, Lac = 1.6 mM with CRLB 14%. C: GA 38 weeks, BW 3515 g, cerebral stroke due to aortic arc thrombus;
PG = 4.2 mM with CRLB 6%. Lac = 3.5 mM with CRLB 9%. Severe reduction of all other metabolites. D: GA 40 weeks, BW 3820 g,
hyperammonemia; PG = 4.2 mM with CRLB 9%, Lac = 1.2 mM with CRLB 18%. The hyperammonemia in this infant also led to
extremely elevated glutamine of 16.6 mM with CRLB 7% (shown in green).
April 2019 1065
Pouwels et al.: Brain Propylene Glycol in Neonates
The concentration of brain lactate was highly variable
between newborns, but did not differ between the infants
with high and low brain PG (0.9 mM [1.4], range
0–3.5 mM vs. 0.6 [0.3], range 0.1–2.3 mM, respectively,
P = 0.07) (Fig. 4). Within the group of newborns who
received phenobarbital (n = 32), we did not observe a conclu-
sive correlation between PG and lactate (Spearman’s rho =
0.29, P = 0.10). Figure 4 shows that data from two infants
with high PG and low lactate inﬂuence the absence of this
correlation. However, within the whole group of 41 infants,
there was a positive correlation (Spearman’s rho = 0.38,
P = 0.015). In none of the spectra did we detect pyruvate, ie,
the median concentration was 0, and Cramer–Rao lower
bounds were well above 50%.
Discussion
This study demonstrated a clear relationship between brain
concentration of PG and the pharmaceutical formulation of
phenobarbital administered to neonates, in particular with
TABLE 1. Demographics and Clinical Data of Neonates With Brain Propylene Glycol (PG) Concentrations Above
1 mM (high PG) and Below 1 mM (low PG)
High PG Low PG
> 1 mM < 1 mM
(n = 18) (n = 23)
Malea 12 (66.7%) 12 (52.2%)
Mortalitya 8 (44.4%) 3 (13%) P = 0.024
Gestational age (weeks)b 38.7 (3.1) 40.4 (3.3)
Birth weight (g)b 3080 (844) 3300 (1242)
Modus partusa Vaginal 6 (35.3%) 7 (30.4%)
Vacuum extraction 4 (23.5%) 7 (30.4%)
Cesarean section 1 (5.9%) 4 (17.4%)
Emergency cesarean 5 (29.4%) 4 (17.4%)
Cesarean under general anesthesia 1 (5.9%) 1 (4.3%)
Diagnosisa Perinatal asphyxia 6 (33.3%) 16 (69.6%)
Perinatal infection 3 (16.7%) 2 (8.7%)
Perinatal stroke 6 (33.3%) 2 (8.7%)
Metabolic disease 1 (5.6%)
Other 2 (11.1%) 3 (13%)
Phenobarbital intravenous solutiona 10 mg/ml 10 (55.6%) 7 (30.4%) P = 0.015d
25 mg/ml 3 (16.7%) 2 (8.7%)
50 mg/ml 3 (16.7%) 5 (21.7%)
10 and 25–50 mg/ml 2 (11.1%)
None 9 (39.1%)
Total PG dose (mg/kg)b,c 1400 (595) 350 (595) P < 0.01
Interval last dose and MRS (hours)b,c 16 (21) 95 (83) P < 0.001
Brain PG (mM)b 3.4 (2.2) 0.02 (0.2) P < 0.001
Parameters are reported as: afrequencies: number (%); bmedian (interquartile range); cPG < 1 mM consists of 14 infants, since 9 infants
did not receive phenobarbital; dcomparison of groups by cross-table and chi-square test. High PG and low PG groups were compared by
chi-square test and Mann–Whitney U-test, as appropriate.
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regard to the concentration of PG used. This relationship was
guided and discovered by quantitative MRS. Although it has
been described decades ago that accumulated PG can be
detected by MRS,17 we were surprised to detect PG concen-
trations as high as 9.5 mM in one infant. The high median
PG level of 3.4 mM in a group of 18 neonates suggests that
peak concentrations have been even higher, since the median
interval between the last phenobarbital administration and
MRS in this group was 16 hours.
The time interval between phenobarbital administration
and MRS examination affected the observed brain PG con-
centrations. In addition, the observed brain PG concentra-
tions were related to the dose and formulation of
phenobarbital used. All phenobarbital solutions that were
used in this study contained 350 mg PG per ml; however,
the concentration of phenobarbital itself varied between
10–50 mg/ml. As a consequence, the use of 10 mg/ml for-
mulations resulted more often in higher brain PG concentra-
tions. With a cumulative dose of up to 40 mg/kg
phenobarbital, usually administered during 1 or 2 consecutive
days, the median cumulative dose of PG was 350 and
1400 mg per kg body weight in neonates with low brain PG
and high brain PG, respectively. These doses clearly exceed
the recommended safety thresholds,2,3 and are also above the
median 34 mg PG per kg/day for which no short-term bio-
chemical adverse effects were observed.7 Neonates receiving
these higher doses of PG may be at higher risk for short-term
adverse effects.1,3,10–12
In the current study, the lack of short-term effects does
not exclude potential adverse effects later in life. To date, the
safe upper limit of intravenous PG remains unknown.
During hepatic elimination, PG is degraded to pyruvate
and lactate.19 We did not observe any pyruvate in the spectra,
and the observed lactate was primarily present in brain tissue,
since the estimated contribution of CSF to the VOI was lim-
ited to a few percent. However, a correlation between brain
lactate and PG was not present in the group of infants who
received phenobarbital as the only source of PG, which is the
only relevant group to test when assuming lactic acidosis due
to PG degradation. This seems to be in contrast to the ﬁnd-
ings by Kelner and Bailey, who reported a correlation
between PG and lactate in CSF and serum in ﬁve patients
(two adults and three infants between 2 and 5 months of
age).20 However, the fact that we also observed high brain
lactate in neonates who did not receive PG at all shows that
there are other explanations for lactate elevation in our
cohort, such as perinatal asphyxia with hypoxic ischemic
injury.23 Currently, we can only speculate that there might
be situations with increased lactate metabolism that may
explain why we do not observe high lactate in all high PG
FIGURE 3: Scatterplot of estimated brain concentration of propylene glycol (PG) vs. total dose PG per kg body weight. Colors
indicate the formulation of phenobarbital administered (red: 10 mg phenobarbital/ml, blue: 25 mg phenobarbital/ml, black: 50 mg
phenobarbital/ml, gray: combination of 10 mg phenobarbital/ml and either 25 or 50 mg phenobarbital/ml). The interval between
the last dose of phenobarbital and MR examination is indicated with circles (<30 hours) and crosses (>30 hours).
FIGURE 4: Observed concentrations of lactate (Lac) and
propylene glycol (PG). There was no conclusive correlation
between concentrations of PG and Lac within the group of
newborns who received phenobarbital (n = 32, Spearman’s
rho = 0.29, P = 0.10). However, within the whole group there
was a positive correlation (n = 41, Spearman’s rho = 0.38,
P = 0.015).
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cases. Although mortality was higher in the high brain PG
group, this could not be attributed to a higher frequency of
speciﬁc medical disease nor to PG administration.
The current study has several limitations. First, we
acknowledge the limitations of a retrospective study. None-
theless, this study is of critical importance in showing that
high brain PG concentrations are reached and are related to
the type of phenobarbital formulation used. Second, the sam-
ple size was limited and the data were limited by data avail-
able from medical records due to the retrospective design of
this study. As a consequence, a power analysis could not be
performed. Further, there was some variability in localization,
volume, and number of averages. Still, spectral quality was
high in all cases, and it may be assumed that the accumula-
tion of PG will be similar in cortex and in deep cortical gray
matter structures. Lastly, unfortunately, our study was not
designed to evaluate either short- or long-term consequences
of PG use. No serum concentrations of PG were available
during the study period. Also, data on biochemical effects of
PG, such as metabolic acidosis, liver enzymes and function,
or renal function were not consistently available, and there-
fore could not be analyzed.
In conclusion, this MRS study showed that brain PG
concentrations are directly related to PG used as a solvent in
phenobarbital intravenous solutions. Although the long-term
effects of PG accumulation are not exactly known, serious
adverse short-term effects are reason enough to select the best
possible pharmaceutical formulation to keep PG levels as low
as possible.
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